These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35770533)

  • 1. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
    Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
    Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
    Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
    Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
    Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
    [No Abstract]   [Full Text] [Related]  

  • 5. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
    Steinauer N; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar AA; Saliba AN; Torghabeh M; Litzow MR; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Yi CA; Tefferi A; Gangat N
    Haematologica; 2024 Aug; 109(8):2706-2710. PubMed ID: 38546692
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
    Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
    Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
    Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Gangat N; Tefferi A
    Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Sevindik OG; Mergen M; Mergen S; Mutlu YG; Aydın BB; Serin I
    Ann Hematol; 2022 Nov; 101(11):2545-2547. PubMed ID: 35906348
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Patel SA
    Br J Haematol; 2024 Apr; 204(4):1137-1138. PubMed ID: 38339780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study.
    Wang M; Cao HY; Tan KW; Qiu QC; Huang YH; Ge SS; Wang ZH; Chen J; Tang XW; Wu DP; Xue SL; Li Z; Dai HP
    Blood Cancer J; 2023 Nov; 13(1):173. PubMed ID: 38012154
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm.
    Gangat N; Ilyas R; McCullough K; Begna KH; Al-Kali A; Patnaik MM; Litzow MR; Hogan WJ; Mangaonkar A; Alkhateeb H; Shah MV; Elliott MA; Foran JM; Badar T; Palmer JM; Hanson CA; Pardanani A; Tefferi A
    Haematologica; 2023 May; 108(5):1423-1428. PubMed ID: 36519330
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
    Gangat N; Ilyas R; Johnson IM; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Tefferi A
    Haematologica; 2023 Nov; 108(11):3170-3174. PubMed ID: 36861409
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
    Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
    Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
    [No Abstract]   [Full Text] [Related]  

  • 17. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    DiNardo CD
    Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
    [No Abstract]   [Full Text] [Related]  

  • 18. Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
    Zainaldin C; Arora S; Bathini S; Gupta U; Pandya V; Bae S; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
    Leuk Lymphoma; 2022 Dec; 63(13):3245-3248. PubMed ID: 36107006
    [No Abstract]   [Full Text] [Related]  

  • 19. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 20. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Jonas BA; Wei AH; Recher C; DiNardo CD; Jang JH; Pratz K; Panayiotidis P; Montesinos P; Yeh SP; Ivanov V; Fiedler W; Yamauchi T; Duan Y; Mendes W; Potluri J; Tews B; Ofran Y
    Am J Hematol; 2022 Aug; 97(8):E299-E303. PubMed ID: 35567776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.